Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00162266 · ClinicalTrials.gov registry record · Phase 2

Abatacept With Methotrexate- Phase IIB

A Phase 2 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
524
Enrollment target
20
Study locations

NCT00162266: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

NCT00162266 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 524 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00162266, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
524 participants
Enrollment target
20
Study locations

Study Summary

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

Primary Outcome

ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed fo

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG Abatacept (BMS-188667)

Study Locations (20)

Florida

  • Local Institution - Largo
  • Local Institution - Titusville
  • Local Institution - West Palm Beach

New York

  • Local Institution - Albany
  • Local Institution - Binghamton
  • Local Institution - The Bronx

Alabama

  • Local Institution - Birmingham
  • Local Institution - Huntsville

Massachusetts

  • Local Institution - Springfield
  • Local Institution - Worcester

New Mexico

  • Local Institution - Albuquerque
  • Local Institution - Los Alamos

California

  • Local Institution - Long Beach

Colorado

  • Local Institution - Highlands Ranch

Georgia

  • Local Institution - Rome

Trial Details

FieldValue
Enrollment Target 524 participants
Start Date 2000-10
Est. Completion 2009-09
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00162266 record still lists

NCT00162266 is an interventional study that assigns participants to a tested intervention. The registered 524 participants enrollment target is mid-sized for trials with a published cap, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00162266 names 20 study sites across 13 states, led by Florida, New York, Alabama.

Frequently Asked Questions

What is clinical trial NCT00162266 about?

NCT00162266 is a clinical study titled "Abatacept With Methotrexate- Phase IIB". This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

What is the current status of trial NCT00162266?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 524 participants. The study started on 2000-10. Estimated completion is 2009-09.

What conditions does trial NCT00162266 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00162266?

The interventions under investigation include: Placebo (DRUG), Abatacept (BMS-188667) (DRUG).

Who is sponsoring clinical trial NCT00162266?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00162266 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00162266's enrollment target sits among peer trials

524 40th of 197 higher than 158 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04580134 · 524 participants · Phase 4

    CLOZAPINE Response in Biotype-1

  • NCT07158814 · 524 participants · Phase 4

    Safety of RSV Preventive Monoclonal Antibody

  • NCT04769492 · 525 participants · NA

    #ChopViolence/#ChopHIV

  • NCT05260047 · 525 participants · NA

    Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00162266, the US trial registry maintained by the National Library of Medicine. NCT00162266 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.